Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 2/20 | 0.42 |
| ▸ | CTSK | P43235 | 3/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | DUT | P33316 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CASR | P41180 | 1/20 | 0.32 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8502919 | 1.00 | TK1 (0.42) | TK1CTSKKIF11CYP2C19TSHR | |
| SCHEMBL7523027 | 0.84 | KIF11 (0.46) | TK1CTSKKIF11CYP2C19TSHR | |
| SCHEMBL2111572 | 0.84 | KIF11 (0.50) | TK1CTSKKIF11CYP2C19TSHR | |
| SCHEMBL27859924 | 0.83 | CA1 (0.45) | TK1CTSKKIF11TSHRALDH1A1 | |
| SCHEMBL8233466 | 0.81 | TK1 (0.39) | TK1CTSKKIF11CYP2C19TSHR | |
| SCHEMBL2111430 | 0.79 | KIF11 (0.43) | TK1CTSKKIF11CYP2C19TSHR | |
| SCHEMBL993538 | 0.79 | KIF11 (0.43) | TK1CTSKKIF11CYP2C19TSHR | |
| SCHEMBL6522822 | 0.79 | TK1 (0.46) | TK1CTSKKIF11CYP2C19TSHR | |
| SCHEMBL465454 | 0.79 | TK1 (0.46) | TK1CTSKKIF11CYP2C19TSHR | |
| SCHEMBL4917240 | 0.77 | KIF11 (0.53) | TK1CTSKKIF11CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042778-A1 | Polymorphs of N-Desmethyl Ruboxistaurin and Salts Thereof | 4M THERAPEUTICS INC. (US) | 2026-02-12 | — | — | US | disclosed |
| EP-1173397-A1 | STEREOSPECIFIC METHOD FOR PREPARING 4-HYDOXYALK-1-ENE COMPOUNDS | PPG-Sipsy S.C.A. (FR) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000066519-A1 | STEREOSPECIFIC METHOD FOR PREPARING 4-HYDOXYALK-1-ENE COMPOUNDS | PPG-SIPSY S.C.A. (FR) | 2000-11-09 | — | — | WO | disclosed |
| EP-0776899-B1 | Intermediates and their use to prepare N,N'-bridged bisindolylmaleimides | LILLY CO ELI (US) | 2000-03-29 | — | — | EP | disclosed |
| EP-0657411-B1 | Synthesis of bisindolylmaleimides | LILLY CO ELI (US) | 1999-06-09 | — | — | EP | disclosed |
| US-5721272-A | PROTEIN KINASE C INHIBITORS | ELI LILLY AND COMPANY (US) | 1998-02-24 | — | — | US | disclosed |
| US-5665877-A | Synthesis of bisindolylmaleimides | ELI LILLY AND COMPANY (US) | 1997-09-09 | — | — | US | disclosed |
| EP-0776899-A1 | Intermediates and their use to prepare N,N'-bridged bisindolylmaleimides | ELI LILLY AND COMPANY (US) | 1997-06-04 | — | — | EP | disclosed |
| WO-1997019080-A1 | NOVEL INTERMEDIATES AND THEIR USE TO PREPARE N,N'-BRIDGED BISINDOLYLMALEIMIDES | ELI LILLY AND COMPANY (US) | 1997-05-29 | — | — | WO | disclosed |
| US-5614647-A | Intermediates for the synthesis of bisindolylmaleimides | ELI LILLY AND COMPANY (US) | 1997-03-25 | — | — | US | disclosed |
| US-5541347-A | Synthesis of bisindolylmaleimides | ELI LILLY AND COMPANY (US) | 1996-07-30 | — | — | US | disclosed |
| EP-0657411-A1 | Improved synthesis of bisindolylmaleimides | ELI LILLY AND COMPANY (US) | 1995-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042778-A1 | Polymorphs of N-Desmethyl Ruboxistaurin and Salts Thereof | GSK3B, GSK3A, LRRK2 | TK1 3161/4885CTSK 1188/4885KIF11 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.